TY - JOUR
T1 - A phase II study of BEZ235 in patients with everolimusresistant, advanced pancreatic neuroendocrine tumours
AU - Fazio, Nicola
AU - Buzzoni, Roberto
AU - Baudin, Eric
AU - Antonuzzo, Lorenzo
AU - Hubner, Richard A.
AU - Lahner, Harald
AU - De Herder, Wouter W.
AU - Raderer, Markus
AU - Teulé, Alexandre
AU - Capdevila, Jaume
AU - Libutti, Steven K.
AU - Kulke, Matthew H.
AU - Shah, Manisha
AU - Dey, Debarshi
AU - Turri, Sabine
AU - Aimone, Paola
AU - Massacesi, Cristian
AU - Verslype, Chris
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Background: This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimusresistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436). Patients and Methods: In stage 1, 11 patients received 400 mg BEZ235 orally twice daily (bid). Due to tolerability concerns, a further 20 patients received BEZ235 300 mg bid. Stage 2 would be triggered by a 16-week progressionfree survival (PFS) rate of =60% in stage 1. Results: As of 30 June, 2014, 29/31 patients had discontinued treatment. Treatment-related grade 3/4 adverse events were reported in eight (72.7%) patients at 400 mg and eight (40.0%) patients at 300 mg, including hyperglycaemia, diarrhoea, nausea, and vomiting. The estimated 16-week PFS rate was 51.6% (90% confidence interval=35.7-67.3%). Conclusion: BEZ235 was poorly tolerated by patients with everolimus-resistant pNETs at 400 and 300 mg bid doses. Although evidence of disease stability was observed, the study did not proceed to stage 2. Pancreatic neuroendocrine tumours (pNETs) are rare malignancies, representing <2% of all pancreatic cancers (1). Several studies suggest that the annual incidence of pNETs, currently reported to be less than one in 100,000, is rising (1-4). pNETs tend to be slow-growing or indolent compared to other types of cancer, such as pancreatic adenocarcinoma, making early detection difficult. Most patients present with metastatic disease and have a poor prognosis, despite the increasing availability of treatment options (4).
AB - Background: This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimusresistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436). Patients and Methods: In stage 1, 11 patients received 400 mg BEZ235 orally twice daily (bid). Due to tolerability concerns, a further 20 patients received BEZ235 300 mg bid. Stage 2 would be triggered by a 16-week progressionfree survival (PFS) rate of =60% in stage 1. Results: As of 30 June, 2014, 29/31 patients had discontinued treatment. Treatment-related grade 3/4 adverse events were reported in eight (72.7%) patients at 400 mg and eight (40.0%) patients at 300 mg, including hyperglycaemia, diarrhoea, nausea, and vomiting. The estimated 16-week PFS rate was 51.6% (90% confidence interval=35.7-67.3%). Conclusion: BEZ235 was poorly tolerated by patients with everolimus-resistant pNETs at 400 and 300 mg bid doses. Although evidence of disease stability was observed, the study did not proceed to stage 2. Pancreatic neuroendocrine tumours (pNETs) are rare malignancies, representing <2% of all pancreatic cancers (1). Several studies suggest that the annual incidence of pNETs, currently reported to be less than one in 100,000, is rising (1-4). pNETs tend to be slow-growing or indolent compared to other types of cancer, such as pancreatic adenocarcinoma, making early detection difficult. Most patients present with metastatic disease and have a poor prognosis, despite the increasing availability of treatment options (4).
KW - BEZ235
KW - Everolimus
KW - MTOR
KW - PI3K
KW - PNETs
UR - http://www.scopus.com/inward/record.url?scp=84961831124&partnerID=8YFLogxK
M3 - Article
C2 - 26851029
AN - SCOPUS:84961831124
SN - 0250-7005
VL - 36
SP - 713
EP - 720
JO - Anticancer Research
JF - Anticancer Research
IS - 2
ER -